Related to Genzyme’s MS Therapy Teriflunomide Shows Positive Initial Results in Third Phase III Trial

• Acorda Obtains FDA Nod for Oral Drug that Improves Walking in MS Patients
  
• Genzyme and Isis Report Positive Phase III Data from Familial Hypercholesterolemia Trial
  
• Genzyme and Arecor Ally to Advance Protein Therapeutics
  
• Genzyme Reports $2B Stock Repurchase and Intended Sale of Three Segments
  
• Roche and Biogen Idec Ditch Phase III RA Program with Ocrelizumab
  
• Genzyme to Give Up $175M in Profits under Consent Decree to Rectify Issues at Production Plant
  
• FDA Approves Genzyme Product for Late-Onset Pompe Disease
  
• Genzyme to Appoint Two Icahn Nominees to Its Board
  
• Cannabis-Based Drug Launched in the U.K. for MS Spasticity
  
• Sanofi-Aventis Reportedly Makes a Play for Genzyme
  
• Spain Approves Cannabis-Derived MS Therapy as GW Pharm Files for New EU Approvals
  
• Genzyme and Isis Complete Phase III Program for LDL-C Reducing Therapy
  
• Monash University Collaborates with Cryo-Cell to Investigate Menstrual Stem Cell Therapy for MS
  
• Genzyme Dismisses Sanofi-Aventis' Public $18.5B Takeover Bid
  
• Canada Grants GW Pharm’s Sativex Full Approval for MS Spasticity
  
• Russian Authorities Become First to Sanction Novartis’ Oral MS Therapy
  
• Genzyme Sells Genetic-Testing Business to LabCorp for $925M
  
• GSK and Genmab Focus on Subcutaneous Ofatumumab for Autoimmune Diseases
  
• PTC Therapeutics Receives $1.6M from FDA Orphan Drug Grant
  
• Novartis Gets FDA OK for MS Therapy and Makes Headway against Cushing Disease